Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations
Year: 2019
Type: article
Study design: Observational Study
Source: Journal of Thoracic Oncology
Authors: Marjorie G. Zauderer, Gowtham Jayakumaran, Mariel DuBoff, Liying Zhang, Jasmine H. Francis, David H. Abramson, Andrea Cercek, Garrett M. Nash, Alexander Shoushtari, Paul Chapman, Sandra D’Angelo, Angela G. Arnold, Beth Siegel, Megan Harlan Fleischut, Andy Ni, Andreas Rimner, Valerie W. Rusch, Prasad S. Adusumilli, William Travis, Jennifer L. Sauter, Ahmet Zehir, Diana Mandelker, Marc Ladanyi, Mark Robson
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, Boehringer Ingelheim, Fred L. Emerson Foundation, Mesothelioma Applied Research Foundation, Amgen, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Roche, North Carolina GlaxoSmithKline Foundation, AbbVie, Memorial Sloan-Kettering Cancer Center, Varian Medical Systems, Helsinn, Society of Memorial Sloan Kettering, ACEA Biosciences, Atara Biotherapeutics, Incyte, Emerson Collective, Aldeyra Therapeutics, Castle Biosciences, Invitae, Daiichi-Sankyo, MedImmune, National Institutes of Health, Genentech, EMD Serono, Helsinn Therapeutics, National Cancer Institute
OpenAlex ID: W2956985211